How has been the historical performance of Aarey Drugs?
Aarey Drugs has shown fluctuating financial performance, with net sales peaking at 492.68 Cr in Mar'22, dropping to 395.62 Cr in Mar'24, and rebounding to 473.94 Cr in Mar'25. While operating profit decreased to 12.70 Cr in Mar'25, cash flow from operations improved significantly to 10.00 Cr, indicating better operational efficiency.
Answer:The historical performance of Aarey Drugs shows a fluctuating trend in net sales and profits over the years, with net sales reaching 473.94 Cr in Mar'25, an increase from 395.62 Cr in Mar'24 but a decrease from 492.68 Cr in Mar'22. The total operating income mirrored this trend, with a peak of 492.68 Cr in Mar'22 and a subsequent decline to 418.96 Cr in Mar'23 before rising again in Mar'25. The operating profit (PBDIT) has also varied, peaking at 14.02 Cr in Mar'22 and dropping to 12.70 Cr in Mar'25. Profit before tax showed a slight increase to 6.10 Cr in Mar'25 from 5.34 Cr in Mar'24, while profit after tax decreased to 4.02 Cr in Mar'25 from 4.68 Cr in Mar'24. The company’s total assets decreased to 290.59 Cr in Mar'25 from 303.29 Cr in Mar'24, while total liabilities also fell to 290.59 Cr from 303.29 Cr in the same period. Cash flow from operating activities improved to 10.00 Cr in Mar'25 from a negative 2.00 Cr in Mar'24, indicating better operational efficiency.Breakdown:
Aarey Drugs has experienced significant fluctuations in its financial performance over the years. Net sales peaked at 492.68 Cr in Mar'22 but fell to 395.62 Cr in Mar'24 before rebounding to 473.94 Cr in Mar'25. Operating profit (PBDIT) followed a similar pattern, with a high of 14.02 Cr in Mar'22, declining to 12.70 Cr in Mar'25. Profit before tax increased slightly to 6.10 Cr in Mar'25, while profit after tax decreased to 4.02 Cr. The company's total assets and liabilities both decreased to 290.59 Cr in Mar'25, reflecting a tightening balance sheet. However, cash flow from operating activities showed a positive turnaround, reaching 10.00 Cr in Mar'25, suggesting improved operational performance despite the overall decline in profits.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
